SCHEMBL7950236

SCHEMBL7950236

COc1cccc(-c2nc(C)sc2C)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.64
HPGD P15428 2/20 0.64
SMN1; SMN2 Q16637 3/20 0.49
NFKB1 P19838 2/20 0.49
RAB9A P51151 2/20 0.49
NFKB2 Q00653 2/20 0.49
RELA Q04206 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
MAPT P10636 1/20 0.49
NISCH Q9Y2I1 1/20 0.48
DYRK1A Q13627 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
ADORA2A P29274 2/20 0.47
PIK3CG P48736 1/20 0.46
DCUN1D1 Q96GG9 1/20 0.46
ADORA2B P29275 1/20 0.45
ADORA1 P30542 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
VDR P11473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20716072 0.84 RAB9A (0.47) ALDH1A1HPGDSMN1; SMN2NFKB1RAB9A
SCHEMBL1398736 0.81 ALDH1A1 (0.52) ALDH1A1HPGDSMN1; SMN2RAB9AADORA2A
SCHEMBL8202114 0.80 ALDH1A1 (0.96) ALDH1A1HPGDSMN1; SMN2TDP1MAPT
SCHEMBL8202097 0.80 ALDH1A1 (0.49) ALDH1A1HPGDSMN1; SMN2RAB9ANISCH
SCHEMBL327291 0.77 MEN1 (0.54) ALDH1A1HPGDSMN1; SMN2NFKB1RAB9A
SCHEMBL2093695 0.77 ALDH1A1 (0.46) ALDH1A1HPGDMAPTNISCHADORA2A
SCHEMBL13545723 0.77 ALDH1A1 (0.46) ALDH1A1HPGDSMN1; SMN2RAB9AMAPT
SCHEMBL2091654 0.77 KDM1A (0.48) ALDH1A1HPGDADORA2AADORA2BADORA1
SCHEMBL1966336 0.77 DHODH (0.59) ALDH1A1HPGDSMN1; SMN2RAB9AMAPT
SCHEMBL2093741 0.75 ALDH1A1 (0.59) ALDH1A1HPGDSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-05-05 US disclosed
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-05-05 US disclosed
WO-2010004507-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-01-14 WO disclosed
WO-2008087611-A2 PYRROLIDINE- AND PIPERIDINE- BIS-AMIDE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, OXTR ALDH1A1 690/4885HPGD 2597/4885SMN1; SMN2 3479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.